Compare Merck & Co., Inc. (MRK) vs Cloudflare Inc (NET) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Cloudflare Inc — how do they compare? Merck & Co., Inc. trades at $147.98 (market cap $363.98B), while Cloudflare Inc trades at $312.83 (market cap $111.87B). The key difference: Merck & Co., Inc. is far larger — about 3.3× Cloudflare Inc's market cap, and Merck & Co., Inc. pays a 2.3% dividend while Cloudflare Inc pays none. Which is the better fit depends on your goals.
| MRK | NET | |
|---|---|---|
Market Cap | $363.98B | $111.87B |
Sector | Health | Technology |
52-Week High | $156.43 | $330.74 |
52-Week Low | $77.60 | $160.16 |
Enterprise Value | $410.75B | $111.24B |
Dividend Yield | 2.3% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MRK trades at $148.49, down 1.23% on the day, with a bullish technical signal from moving averages and support near $147. The company reported strong earnings beats in recent quarters, with Q3 2026 EPS expected at $2.22. Revenue reached $65.01B in 2025, and the acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline.
Outlook remains positive with a consensus price target of $157, offering ~6% upside. Risks include high P/E of 118.77 and competitive pressures in pharma. Institutional buying and a 67.57% buy rating from analysts support a constructive view, though net income margin of 4.77% warrants monitoring.
Cloudflare (NET) trades at $284.41, up 1.97% with strong quarterly earnings beats and positive AI-driven momentum. The stock shows bullish moving averages but neutral oscillators, with key resistance at $292. Revenue growth remains robust at $2.17B for 2025, though profitability challenges persist with a -8.21% net margin. Recent partnerships with OpenAI and government security clearances provide significant growth catalysts.
Outlook remains positive with 72.5% analyst buy ratings and a $347.89 consensus target, representing 22% upside. Key risks include premium valuation (P/S 39.82), ongoing net losses, and competitive pressures in cybersecurity. The AI security positioning and federal contract potential offer substantial growth opportunities if execution succeeds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Cloudflare Inc
Cloudflare is a software company based in San Francisco, California, that offers security and web performance offerings by utilizing a distributed, serverless content delivery network, or CDN. The firm's edge computing platform, Workers, leverages this network by providing clients the ability to deploy, and execute code without maintaining servers.
Read more on NET →
